Mylan Pharma UK Ltd.
🇬🇧United Kingdom
- Country
- 🇬🇧United Kingdom
- Ownership
- Subsidiary
- Established
- 1961-01-01
- Employees
- -
- Market Cap
- -
- Website
- http://www.mylan.co.uk
Clinical Trials
12
Active:6
Completed:5
Trial Phases
3 Phases
Phase 1:4
Phase 3:2
Not Applicable:1
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (7 trials with phase data)• Click on a phase to view related trials
Phase 1
4 (57.1%)Phase 3
2 (28.6%)Not Applicable
1 (14.3%)Fasting Bioavailability Study of Mylan's Revefenacin Inhalation Solution
Phase 1
Completed
- Conditions
- Healthy Volunteers Bioavailability Study
- Interventions
- First Posted Date
- 2022-01-26
- Last Posted Date
- 2022-04-04
- Lead Sponsor
- Mylan Pharma UK Ltd.
- Target Recruit Count
- 24
- Registration Number
- NCT05207111
- Locations
- 🇨🇳
Xuzhou Central Hospital, Xuzhou, China
Revefenacin in Chinese Subjects With Moderate to Very Severe Chronic Obstructive Pulmonary Disease(COPD)
Phase 3
Completed
- Conditions
- COPD
- Interventions
- Drug: Placebo inhalation solution QD
- First Posted Date
- 2021-09-16
- Last Posted Date
- 2024-11-01
- Lead Sponsor
- Mylan Pharma UK Ltd.
- Target Recruit Count
- 258
- Registration Number
- NCT05046795
- Locations
- 🇨🇳
Anhui Medical University - Hefei First People's Hospital, Hefei, Anhui, China
🇨🇳Peking University Third Hospital, Beijing, Beijing, China
🇨🇳Beijing Hospital, Beijing, Beijing, China
An Open Study to Assess the Robustness of the CRC749 Inhaler
- First Posted Date
- 2015-06-17
- Last Posted Date
- 2022-03-07
- Lead Sponsor
- Mylan Pharma UK Ltd.
- Target Recruit Count
- 111
- Registration Number
- NCT02474017
- Locations
- 🇬🇧
Mylan Investigational Site, Manchester, United Kingdom
MGR001 / Advair Diskus Local Equivalence Study in Asthma
Phase 3
Completed
- Conditions
- Asthma
- Interventions
- Drug: PlaceboDrug: MGR001 (Fixed dose combination of Fluticasone propionate and salmeterol xinafoate)
- First Posted Date
- 2014-09-19
- Last Posted Date
- 2022-02-24
- Lead Sponsor
- Mylan Pharma UK Ltd.
- Target Recruit Count
- 1128
- Registration Number
- NCT02245672
- Locations
- 🇺🇸
Mylan Investigative Site #1, Birmingham, Alabama, United States
🇺🇸Mylan Investigative Site #2, Little Rock, Arkansas, United States
🇺🇸Mylan Investigative Site #3, Anaheim, California, United States
Bioequivalence Study to Assess Systemic Exposure of FP and SAL FDC From Different DPIs
Phase 1
Completed
- Conditions
- AsthmaCOPD
- Interventions
- First Posted Date
- 2014-08-13
- Last Posted Date
- 2022-03-07
- Lead Sponsor
- Mylan Pharma UK Ltd.
- Target Recruit Count
- 40
- Registration Number
- NCT02215122
- Locations
- 🇺🇸
Worldwide Clinical Trials Early Phase Services, San Antonio, Texas, United States
News
No news found